Objectives The aim of this study is to explore the relationship between ganciclovir exposure
and clinical efficacy and/or safety in non‐renal solid organ transplant (SOT) recipients …

Background: Cytomegalovirus causes morbidity and mortality, especially in
immunocompromised patients, and is treated with (val) ganciclovir. Therapeutic drug …

Background Valganciclovir, the oral prodrug of ganciclovir, has been demonstrated
equivalent to iv ganciclovir for CMV disease treatment in solid organ transplant recipients …

Introduction: Cytomegalovirus (CMV) is an opportunistic infectious complication that can
occur after allogeneic hematopoietic cell transplantation (HCT). The mainstay of treatment …

Cytomegalovirus (CMV) breakthrough despite therapy with ganciclovir remains a problem,
particularly for solid organ transplant (SOT) patients. This could be owing to inadequate …

Objective To study the impact of initial cytomegalovirus (CMV) viral load on virological
response to ganciclovir preemptive therapy in allogeneic stem cell transplant (SCT) …

Background. The optimal regimen for the prevention and treatment of cytomegalovirus
(CMV) disease in solid organ transplant recipients remains to be defined, particularly for …

The authors use a previously published decision-making algorithm to address the role of
clinical pharmacokinetic monitoring of ganciclovir, the drug of choice for prophylaxis and …

ABSTRACT A population pharmacokinetics analysis was performed after intravenous
ganciclovir and oral valganciclovir in solid organ transplant patients with cytomegalovirus …

It is uncertain whether monitoring plasma ganciclovir (GCV) levels is useful in predicting
cytomegalovirus (CMV) DNAemia clearance in preemptively treated allogeneic stem cell …